Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.
Tatsuya NaganoMasahiro KatsuradaYuichiro YasudaKazuyuki KobayashiYoshihiro NishimuraPublished in: Therapeutic advances in respiratory disease (2020)
Smoking causes various diseases and is a major public health threat worldwide. Therefore, promoting smoking cessation is the most important intervention contributing to maintaining the health of smokers and nonsmokers and saving enormous financial expense. We reviewed existing and emerging smoking-cessation pharmacotherapies from the Cochrane Database of Systemic Reviews, PubMed, Ovid, and ClinicalTrials.gov databases. A literature review revealed that bupropion may be appropriate for patients interested in reducing smoking who dislike, or who have failed, nicotine-replacement therapy (NRT). Additionally, varenicline and NRT are efficacious first-line smoking cessation treatments and should be given to all individuals unless contraindicated. The reviews of this paper are available via the supplementary material section.
Keyphrases
- smoking cessation
- replacement therapy
- public health
- end stage renal disease
- clinical trial
- randomized controlled trial
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- single cell
- phase ii
- big data
- social media
- global health
- health information
- open label
- young adults
- adverse drug